PDX Antibodies

Santa Cruz Biotechnology provides a broad selection of PDX Antibodies for studying patient-derived xenograft models. PDX Antibodies are suitable for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Patient-derived xenografts are critical for understanding tumor biology and therapeutic responses, as they maintain the heterogeneity of the original patient tumors. PDX Antibodies target specific proteins involved in cancer progression, metastasis, and treatment resistance, making them significant for translational research. By studying PDX models, researchers can gain insights into the molecular mechanisms underlying cancer and develop more effective treatment strategies. PDX Antibodies enable detailed analysis of tumor growth patterns and drug responses in preclinical studies. Understanding PDX models helps bridge the gap between laboratory findings and clinical applications. Investigating PDX models with monoclonal antibodies from Santa Cruz Biotechnology supports the development of personalized cancer treatments and advances in oncology research.